SETDB1 and cancer: Our demonstration that SETDB1 loss in hypoxia robustly de-represses TEs, triggering DNA damage-induced cell death, suggests that targeting SETDB1 could serve as a useful therapeutic strategy for directed treatment of cancer cells in the hypoxic TME.